EUCTR2004-005032-35-IT进行中（未招募）不适用
A Phase III, Multicentre, Pan-European, Randomised, Double-Blind, Double-Dummy, Active Comparator Controlled, Parallel Group Study of Targeted Release Prednisolone in Treatment of Moderate, Acute Ulcerative Colitis
ALIZYME0 个研究点目标入组 890 人开始时间: 2007年1月19日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 890
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
A EUROPEAN PHASE III, MULTICENTRE, DOUBLE-BLIND, RANDOMISED, MONOTHERAPY, 12-MONTH STUDY OF MILNACIPRAN FOR THE TREATMENT OF THE FIBROMYALGIA SYNDROME - FMS European Long-Term StudyFibromyalgia syndrome (FMS) is a common systemic rheumatologic disorder estimated to affect 2 to 4% of the population.Fibromyalgia is associated with a reduced threshold for pain, generally identified by increased sensibility to pressure at particular points on the body, and is often accompanied by fatigue, sleep disturbance and morning stiffness.Other common symptoms include headhache, migraine, variable bowel habits, diffuse abdominal pain and urinary frequency.MedDRA version: 9.1Level: LLTClassification code 10016631Term: Fibromyalgia syndromeEUCTR2006-001230-41-PTPIERRE FABRE MEDICAMENT420
进行中（未招募）
不适用
A EUROPEAN PHASE III, MULTICENTRE, DOUBLE-BLIND, RANDOMISED, MONOTHERAPY, 12-MONTH STUDY OF MILNACIPRAN FOR THE TREATMENT OF THE FIBROMYALGIA SYNDROME - FMS European Long-Term StudyFibromyalgia SyndromeMedDRA version: 9.1Level: LLTClassification code 10048439Term: FibromyalgiaEUCTR2006-001230-41-ITPIERRE FABRE MEDICAMENT420
进行中（未招募）
不适用
A EUROPEAN PHASE III, MULTICENTRE, DOUBLE-BLIND, RANDOMISED, MONOTHERAPY, 12-MONTH STUDY OF MILNACIPRAN FOR THE TREATMENT OF THE FIBROMYALGIA SYNDROME - FMS European Long-Term StudyFibromyalgia syndrome (FMS).FMS is a common systemic rheumatologic disorder estimated to affect 2 to 4% of the population.Fibromyalgia is associated with a reduced threshold for pain, generally identified by increased sensibility to pressure at particular points on the body, and is often accompanied by fatigue, sleep disturbance and morning stiffness.Other common symptoms include headhache, migraine, variable bowel habits, diffuse abdominal pain and urinary frequency.MedDRA version: 8.1Level: LLTClassification code 10016631Term: Fibromyalgia syndromeEUCTR2006-001230-41-DKPIERRE FABRE MEDICAMENT420
进行中（未招募）
不适用
A EUROPEAN PHASE III, MULTICENTRE, DOUBLE-BLIND, RANDOMISED, MONOTHERAPY, 12-MONTH STUDY OF MILNACIPRAN FOR THE TREATMENT OF THE FIBROMYALGIA SYNDROME - FMS European Long-Term StudyFibromyalgia syndrome (FMS) is a common systemic rheumatologic disorder estimated to affect 2 to 4% of the population.Fibromyalgia is associated with a reduced threshold for pain, generally identified by increased sensibility to pressure at particular points on the body, and is often accompanied by fatigue, sleep disturbance and morning stiffness.Other common symptoms include headhache, migraine, variable bowel habits, diffuse abdominal pain and urinary frequency.MedDRA version: 8.1Level: LLTClassification code 10016631Term: Fibromyalgia syndromeEUCTR2006-001230-41-SEPIERRE FABRE MEDICAMENT556
进行中（未招募）
不适用
A EUROPEAN PHASE III, MULTICENTRE, DOUBLE-BLIND, RANDOMISED, MONOTHERAPY, 12-MONTH STUDY OF MILNACIPRAN FOR THE TREATMENT OF THE FIBROMYALGIA SYNDROME - FMS European Long-Term StudyEUCTR2006-001230-41-GBPIERRE FABRE MEDICAMENT400